Monitoring microvascular function in critically ill patients using near-infrared spectroscopy
Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS): Prospective Observational Cohort Study
University of Manitoba · NCT05985525
This study is trying to see if a special light technology can safely check blood flow in the tiny blood vessels of critically ill patients in the ICU to help understand their health better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Manitoba (other) |
| Locations | 1 site (Winnipeg, Manitoba) |
| Trial ID | NCT05985525 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the feasibility of using near-infrared spectroscopy (NIRS) to monitor microvascular function in critically ill patients admitted to the ICU. It involves the non-invasive application of NIRS monitors to assess skeletal muscle and brain microvascular metrics throughout the patient's ICU stay. Continuous vital signs and clinical data will be collected to explore the relationship between these metrics and ICU mortality, aiming to enhance understanding of microvascular health in sepsis and shock.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill patients who are admitted to the ICU and receiving invasive mechanical ventilation.
Not a fit: Patients with a body mass index over 40 or those who are imminently dying may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring of microvascular function, potentially enhancing patient outcomes in critical illness.
How similar studies have performed: While the use of NIRS in monitoring microvascular function is promising, this specific approach in critically ill patients is still being explored and may not have extensive prior success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted to ICU * Receiving invasive mechanical ventilation Exclusion Criteria: * Body Mass Index \>40 * More than 24 hours has elapsed since ICU admission * Death is deemed to be imminent and inevitable during the next 24 hours * Known allergy to the textile components of the device * Significant clinical jaundice, ecchymosis * COVID positive microbiological result * The treating clinician believes that participation in the domain would not be in the best interests of the patient * Consent declined from patient or authorized third party
Where this trial is running
Winnipeg, Manitoba
- Health Sciences Centre Winnipeg — Winnipeg, Manitoba, Canada (RECRUITING)
Study contacts
- Principal investigator: Asher Mendelson, MD, PhD — University of Manitoba
- Study coordinator: Asher Mendelson, MD, PhD
- Email: asher.mendelson@umanitoba.ca
- Phone: 2047871634
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, Shock, Critical Illness, Near-Infrared Spectroscopy